SCHEMBL5004602

SCHEMBL5004602

CCCc1noc(C2CC(N3CCCC(C(=O)O)C3)C2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 3/20 0.41
HSD11B1 P28845 5/20 0.39
CHRM2 P08172 2/20 0.38
CHRM4 P08173 2/20 0.38
CHRM5 P08912 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
S1PR1 P21453 3/20 0.37
S1PR3 Q99500 3/20 0.37
RAB9A P51151 2/20 0.37
TSHR P16473 1/20 0.36
SCN9A Q15858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5007431 0.86 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1HSD11B1CHRM2CHRM4
SCHEMBL5004068 0.81 CCR5 (0.45) SMN1; SMN2ALDH1A1HSD11B1CHRM4TSHR
Oxalic Acid SCHEMBL9702684 0.74 CHRM2 (0.51) CHRM2CHRM4CHRM5CHRM1CHRM3
Oxalic Acid SCHEMBL9702698 0.74 CHRM2 (0.51) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL11967082 0.69 RAB9A (0.40) SMN1; SMN2ALDH1A1CHRM2CHRM4CHRM5
SCHEMBL5007422 0.69 EPHX2 (0.43) SMN1; SMN2ALDH1A1HSD11B1CHRM2RAB9A
SCHEMBL642327 0.68 F2R (0.52) ALDH1A1HSD11B1TSHRGRM5
SCHEMBL5007409 0.66 AKR1C3 (0.51) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5004640 0.65 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1RAB9ATSHRNPC1
SCHEMBL2300245 0.65 GPR119 (0.39) SMN1; SMN2ALDH1A1CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 SMN1; SMN2 4085/4885ALDH1A1 3777/4885HSD11B1 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.